Clinical Trials at Idaho Urologic Institute-Meridian
As of August 2026, 32 paid clinical trials are recruiting at Idaho Urologic Institute-Meridian, located at 2855 E MAGIC VIEW DR, MERIDIAN, ID 83642-6245, phone (208) 639-4900 in Meridian, Idaho. Active studies at this site cover conditions such as Obesity, Acute Myeloid Leukemia and Anatomic Stage II Breast Cancer AJCC v8. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
32 clinical trials at Idaho Urologic Institute-Meridian
·Clear filters·Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Family Communications After Genetic Testing
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Common conditions studied in Meridian
- Obesity (7 active studies)
- Acute Myeloid Leukemia (6 active studies)
- Anatomic Stage II Breast Cancer AJCC v8 (4 active studies)
- Malignant Solid Neoplasm (4 active studies)
- Overweight (4 active studies)
- Stage IIIB Lung Cancer AJCC v8 (3 active studies)
Leading research sponsors in Meridian
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
- SWOG Cancer Research Network
- ECOG-ACRIN Cancer Research Group
- NRG Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in Meridian?
There are approximately 97 recruiting clinical trials in Meridian, Idaho listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Meridian pay participants?
Most recruiting trials in Meridian compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Meridian?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Meridian?
The most common conditions under active study in Meridian include Obesity (7), Acute Myeloid Leukemia (6), Anatomic Stage II Breast Cancer AJCC v8 (4), Malignant Solid Neoplasm (4), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Meridian?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Meridian on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Meridian?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Meridian?
Recruiting research sites in Meridian include Saint Luke's Cancer Institute - Meridian, Idaho Urologic Institute-Meridian, Solaris Clinical Research, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Meridian right now?
The largest active categories in Meridian are Cancer & tumors (57), Diabetes & metabolic (10), Neurology & pain (4). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Idaho Urologic Institute-Meridian?
Idaho Urologic Institute-Meridian is located at 2855 E MAGIC VIEW DR, MERIDIAN, ID 83642-6245. Use the Google Maps link in the intro above to get directions.
How do I contact Idaho Urologic Institute-Meridian?
You can reach Idaho Urologic Institute-Meridian by phone at (208) 639-4900. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.